ClinicalTrials.gg

Nausea clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 644 studies for Nausea across more than 10 countries. 85 are recruiting or about to start. 257 of them are mainly about Nausea (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10. Counting its narrower condition Postoperative Nausea and Vomiting too: 1,219 studies, 192 open.

ClinicalTrials.gov finds 1,596 studies for Nausea. How that becomes 644 here

This page counts the studies the registry files under Nausea, and those it files under no condition that list Nauseathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,596Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −573Filed under a narrower condition, counted on its own pagePostoperative Nausea and Vomiting 571
  3. −172List Nausea as a condition, but the registry did not file them under itMost often written as “Chemotherapy-induced Nausea and Vomiting” (85), “Chemotherapy Induced Nausea and Vomiting” (14), and “Chemotherapy-Induced Nausea and Vomiting (CINV)” (13). The registry filed them under other conditions only, most often Vomiting (161) and Neoplasms (15).
  4. −207Match it another way191 name it in the title and 16 in a keyword.
  5. 644The count on this page15 of them list Nausea in their own words; the registry filed them under no condition.

Status

Completed
399
Status unknown
69
Terminated
54
Recruiting
51
Not yet recruiting
26
Withdrawn
25

Phase

Phase 2
122
Phase 3
101
Phase 4
85
Phase 1
41
Early Phase 1
5

Where

United States
290
Turkey
55
China
42
Canada
40
Italy
21
France
20

Who develops what

Add Nausea to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 9 programs from 7 companies, 6 with this as their studies’ main aim; 1 with a live phase 3 study; 4 primary completions in the next 12 months. Compare Bristol-Myers Squibb, Eli Lilly and HALEON here →

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
OndansetronRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07681076 · Bristol-Myers Squibb · Phase 4 · live · background · “Ondansetron” · registered Jun 2026
  • NCT06904235 · Helsinn Healthcare SA · Phase 2 · live · comparator · “Reference Treatment: IV ondansetron infusion” · registered Dec 2024
  • NCT01732458 · Merck & Co., Inc · Phase 2 · comparator · “Ondansetron” · registered Nov 2012
  • NCT01636947 · Merck & Co., Inc · Phase 4 · background · “Ondansetron” · registered Jul 2012
  • NCT00891761 · GlaxoSmithKline · Phase 3 · background · “Ondansetron” · registered Apr 2009
Merck & Co., Inc14% of its industry studies22 studies

6 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
tradipitantApproved: US 2025☆ Track1 live phase-3 study: NCT07446439Vanda Pharmaceuticals

The 1 in phase 3 with the nearest primary completion, of 9 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (4)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Nov 2026 est.xanomeline, trospium · Bristol-Myers Squibb · Phase 4 main aimstudied with Ondansetronstudied with trimethobenzamidestudied with MeclizineNCT07681076 Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers — primary endpoint: Number of participants with Treatment Emergent Adverse Events (TEAEs) · 180 enrolled
  • Dec 2026 est.GIPR Agonist LY3537021 · Eli Lilly and Company · Phase 2 main aimNCT07169851 A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer — primary endpoint: Proportion of Participants with a Complete Response (CR) in the Delayed Phase of CINV · 204 enrolled
  • 1 Dec 2026 est.tradipitant · Vanda Pharmaceuticals · Phase 3 main aimNCT07446439 A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use — primary endpoint: Proportion of participants with at least 1 vomiting episode per week in the tradipitant group compared to the placebo group as measured by a daily symptom diary. · 280 enrolled

1 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Nausea studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antiemetics 6 open · NK1 receptor antagonists 3 open · CGRP receptor antagonists 3 open · 5-HT3 antagonists 2 open · Antipsychotics 2 open

Coming up

34studies finish main data collection within a year9 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 51 Nausea studies recruiting now, 21 (41%) set no upper age limit and 19 (37%) stop at 75 or younger. 10 (20%) take children under 18. 5 (10%) are for women only and 0 (0%) for men only; 13 (25%) take healthy volunteers.

Recruiting studies that take each age, of 51
AgeWomenMen
106 (12%)6 (12%)
1844 (86%)40 (78%)
3044 (86%)39 (76%)
4044 (86%)39 (76%)
5042 (82%)39 (76%)
6543 (84%)40 (78%)
7538 (75%)35 (69%)
8531 (61%)28 (55%)

Across all 644 studies, recruiting or not: 43% stop at 75 or younger and 34% at 65; 15% take children; 20% are for women only and 1% for men only; 21% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Nausea studies take

Of 43 phase 3 interventional studies under Nausea, half reached primary completion within 26 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 14 mo2–8 · 18 studies——
Phase 224 mo12–43 · 34 studies——
Phase 326 mo12–51 · 43 studies——
Phase 412 mo7–24 · 27 studies——
Interventional, no phase13 mo5–28 · 126 studies—13 mo6–28 · 120 studies
Observational33 mo15–48 · 28 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 644. Browse all 644 → or search them.